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Introduction: Pneumocystis pneumonia (PCP) is one of the most prevalent opportunistic infections in patients
undergoing immunosuppressive therapy. In this article, we discuss risk factors for PCP development in patients with
rheumatoid arthritis (RA) during the course of biologic therapy and describe a prophylactic treatment for PCP with
trimethoprim/sulfamethoxazole (TMP/SMX). We also evaluate the effectiveness and safety of the treatment.
Methods: We retrospectively analyzed 702 RA patients who received biologic therapy and compared the
characteristics of patients with vs. without PCP to identify the risk factors for PCP. Accordingly, we analyzed 214
patients who received the TMP/SMX biologic agents as prophylaxis against PCP at the start of treatment to
evaluate their effectiveness and safety.
Results: We identified the following as risk factors for PCP: age at least 65 years (hazard ratio (HR) = 4.37, 95%
confidence interval (CI) = 1.04 to 18.2), coexisting pulmonary disease (HR = 8.13, 95% CI = 1.63 to 40.0), and use of
glucocorticoids (HR = 11.4, 95% CI = 1.38 to 90.9). We employed a protocol whereby patients with two or three risk
factors for PCP would receive prophylactic treatment. In the study with 214 patients, there were no cases of PCP,
and the incidence of PCP was reduced to 0.00 per 100 person-years compared with that before the procedure
(0.93 per 100 person-years). There were no severe adverse events induced by the TMP/SMX treatment.
Conclusions: RA patients with two or three risk factors for PCP who are receiving biologic therapy can benefit from
safe primary prophylaxis.Introduction
A paradigm shift in the treatment of rheumatoid arthritis
(RA) has been brought about by the introduction of bio-
logic agents. Special attention should be given to oppor-
tunistic infections in RA patients treated with biologics.
The strict postmarketing surveillance of an anti-tumor ne-
crosis factor α (anti-TNFα) agent, etanercept (ETN), in
Japan showed that 1,206 (8.7%) of 13,894 patients deve-
loped infections and 334 patients (2.4%) developed severe
infections [1]. Authors of several reports have identified
severe infections in patients receiving other biologics and* Correspondence: tanaka@med.uoeh-u.ac.jp
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distribution, and reproduction in any mediumhave indicated the significance of prophylaxis for oppor-
tunistic infections in RA patients.
Pneumocystis pneumonia (PCP) is one of the most
prevalent opportunistic infections, and it can lead to po-
tentially lethal respiratory dysfunction in patients with
HIV infection. It is also observed in patients with auto-
immune diseases undergoing immunosuppressive treat-
ment [2]. Takabayashi et al. reported that PCP developed
in 9 (1.2%) of 761 patients with autoimmune diseases [3].
It has been demonstrated that PCP in non-HIV patients is
more rapidly progressive and fatal than in it is in HIV pa-
tients [4]. Several cases of PCP in Crohn’s disease patients
who were receiving infliximab (IFX) have been reported
[5-7]. Authors of other reports have shown that PCP de-
veloped in patients with RA during the course of biologic
therapy. Postmarketing surveillance in Japan revealed thattral Ltd. This is an Open Access article distributed under the terms of the
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25 (0.18%) of 13,894 patients receiving ETN developed
PCP [1].
It is well-known that HIV patients with a CD4+ cell
count less than 200 cells/mm3 are likely to develop PCP
and that the most common identifiable risk factor for
developing PCP in patients with autoimmune disease or
malignancy is the use of glucocorticoids [9,10]. However,
there have been few published reports on the risk factors
for PCP development in patients with RA who are
receiving biologics, possibly because of the low incidence
and small degree of recognition of PCP in Western
countries.
In this study, we first retrospectively analyzed patients
with RA who had started treatment with biologic agents
(TNFα or interleukin 6 (IL-6) inhibitors) before September
2009 to identify the risk factors for PCP development
and determined the primary prophylactic procedure. The
prophylactic procedure was applied to RA patients who
started treatment with biologics between October 2009
and September 2010, then we retrospectively analyzed
these cases to estimate the effectiveness and safety of the
procedure.
Methods
First cohort study to detect risk factors for developing
Pneumocystis pneumonia
We retrospectively analyzed 702 traceable patients with
RA who had started treatment with biologic agents be-
tween April 2005 and September 2009 in the First Depart-
ment of Internal Medicine, University of Occupational and
Environmental Health (Fukuoka, Japan). During the first
step, we compared the clinical features and laboratory data
between patients who developed PCP and the remaining
patients who did not receive trimethoprim-sulfametho-
xazole (TMP/SMX) prophylaxis. The following clinical pa-
rameters were evaluated to identify risk factors for the
development of PCP: age, the duration of RA, the Disease
Activity Score in 28 joints score and erythrocyte sedimen-
tation rate (DAS28 ESR), coexisting pulmonary disease,
diabetes mellitus (DM), ratio of patients who received
glucocorticoid treatment, dose of glucocorticoid, dose of
methotrexate (MTX), serum immunoglobulin G (IgG) and
serum KL-6. Before starting biologic therapy, all patients
underwent a bidirectional chest X-ray and/or chest com-
puted tomography (CT) to identify coexisting pulmonary
disease, including interstitial pneumonia, pleuritis, diffuse
panbronchiolitis, bronchiectasia, old tuberculosis and in-
flammatory nodules. We excluded the patients who were
proven soon after the initiation of biologic agents to have
complications due to either malignancy or HIV, which in-
fluence the risk for PCP development.
TMP/SMX prophylaxis was begun when each phy-
sician considered a patient to be at relatively high riskfor PCP based on factors including age, dose of gluco-
corticoid, serum IgG level, coexisting pulmonary disease
and complications of DM.
We compared the characteristics of patients in the
PCP group were compared with those in patients with-
out PCP determined risk factors for PCP development.
The sensitivity and specificity of the combination of risk
factors were used to plan the primary prophylactic pro-
cedure, and that procedure was applied to patients with
RA who initiated treatment with biologic agents starting
in October 2009.
Second cohort study to estimate effectiveness and safety
of prophylaxis
We analyzed 214 patients who initiated biologic therapy
between October 2009 and September 2010 to estimate
the incidence of PCP, the continuation rate and the adverse
events associated with TMP/SMX prophylaxis during the
observation period. The observation period was continued
after TMP/SMX withdrawal.
Pneumocystis pneumonia prophylaxis
One tablet containing 80 mg of trimethoprim and 400 mg
of sulfamethoxazole was given every day, or two tablets
were given three times weekly as prophylaxis against PCP,
and the doses were tapered in patients with renal dysfunc-
tion. TMP/SMX was changed to inhaled aerosolized pen-
tamidine in patients who experienced adverse events due
to TMP/SMX treatment. They inhaled aerosolized pen-
tamidine at a dose of 300 mg once monthly.
Diagnosis of Pneumocystis pneumonia
A diagnosis of PCP was presumed when a patient with
fever and nonproductive cough had progressive hypo-
xemia and interstitial pneumonia detected by chest X-ray
and/or chest CT and was diagnosed on the basis of posi-
tivity for Pneumocystis jirovecii in the sputum or broncho-
alveolar lavage fluid (BALF) by PCR and/or by elevated
concentration of β-D-glucan.
Statistical analysis
For comparison of the PCP and non-PCP groups, we used
the Wilcoxon rank-sum test. Logistic regression analysis
was performed to determine risk factors for PCP develop-
ment by JMP 9.0. A P value < 0.05 was taken as statisti-
cally significant.
Ethical considerations
This study is compliant with the Declaration of Helsinki,
and the study protocol was approved by the Ethics Com-
mittee of the University of Occupational and Environ-
mental Health School of Medicine. Informed consent to
participate in the study and have information published
was obtained from each patient.
Katsuyama et al. Arthritis Research & Therapy 2014, 16:R43 Page 3 of 8
http://arthritis-research.com/content/16/1/R43Results
First study identified three risk factors for Pneumocystis
pneumonia development
In the study to develop the prophylactic procedure, we
evaluated 702 patients with RA who were being treated
with biologic therapy (281 patients treated with IFX, 197
with ETN, 117 with adalimumab (ADA) and 107 with
tocilizumab (TCZ)). The patient population comprised
574 females (81.7%) and 128 males (18.3%). The mean
age of the patients when they received their first biologic
agent was 58.0 years (range, 14 to 86 years) (Table 1).
The mean observation period was 16.6 months (range,
2 weeks to 60 months) and 141 patients (20.1%) received
TMP/SMX prophylaxis. A total of 265 patients (37.7%)
had coexisting pulmonary disease, 303 patients (43.2%)
received glucocorticoid therapy and the mean dose
(±SD) of glucocorticoid (converted to the prednisolone
(PSL) equivalent) was 4.46 mg ± 3.64 mg. We included
not only active lung disease but also nonactive lung le-
sions, including inactive pulmonary fibrosis as coexisting
pulmonary disease, which resulted in the high ratio of
patients with coexisting lung disease. A total of 78.5% of
patients were given MTX, and the average dose of MTX
in patients treated with MTX was 8.96 mg/wk.
Nine (1.28%) of the seven hundred two patients deve-
loped PCP, and none of the patients in the group treated
with TMP/SMX prophylaxis developed PCP. Four ofTable 1 Comparison of baseline characteristics of two
cohortsa
Characteristics Before After P-value
Patients, n 702 214
Observation period (person-years) 972.9 101.4
Females, n (%) 578 (82.3) 174 (81.3) 0.851
Age (years) 58.0 ± 14.3 58.9 ± 15.5 0.642
RA duration (months) 112 ± 125 92.9 ± 119 0.037
DAS28 score (ESR) 5.83 ± 1.24 5.45 ± 1.27 0.001
Coexisting pulmonary disease (%) 37.7 65.8 0.001
Diabetes mellitus (%) 12.7 9.80 0.268
Glucocorticoids (%)b 43.2 22.9 0.001
Methotrexate (%)c 78.5 87.9 0.002
Dose of methotrexate (mg/wk) 8.96 ± 2.46 9.51 ± 2.51 0.007
Serum level of IgG (mg/dl) 1590 ± 522 1600 ± 876 0.131
Serum level of KL-6 (U/ml) 271 ± 147 250 ± 194 0.086
aDAS28: Disease Activity Score in 28 joints; ESR: Erythrocyte sedimentation
rate; IgG: Immunoglobulin G. bThe use of glucocorticoids data are the
percentage of patients treated with glucocorticoids. cThe use of methotrexate
data are the percentage of patients treated with methotrexate. Compared
with the group of 702 patients, the duration of RA was shorter and DAS28
score (ESR), the complication of pulmonary disease, and the use and dose of
glucocorticoids were lower in 214 patients. The dose of methotrexate was
increased after the adoption of the prophylaxis criterion. Data are mean ± SD
by Wilcoxon rank-sum test.nine patients with PCP were receiving the prophylactic
treatment at the initiation of biologic therapy, although all
of them stopped the prophylaxis (because of side effects of
prophylaxis in two patients and for unknown reasons in
two patients). The other five patients were not receiving
the prophylaxis during the treatment with biologics. The
mean interval between the first infusion of the biologic
agent and the onset of PCP was 7.17 months (range,
2 weeks to 20 months). The mean age of patients with
PCP at the start of biologic therapy was 69.5 years (range,
57 to 78 years), and the mean morbidity period of RA for
the PCP patients was 76.3 months (Table 2). Coexisting
pulmonary disease was detected in seven (77.8%) of the
nine patients. Eight patients (88.9%) who developed PCP
were receiving glucocorticoid therapy at a mean dose
(±SD) of 8.83 mg ± 14.9 mg. Six (66.7%) of the nine pa-
tients were given MTX, and the average dose of MTX
given to them was 9.83 mg/wk. The average in the nine
patients was 6.56 mg/wk.
Because TMP/SMX is known to inhibit the development
of PCP almost completely, we excluded from the analysis
the 141 patients treated with the prophylaxis. We first an-
alyzed the characteristics of these 141 patients who were
thought to be at high risk for the development of PCP and
received the prophylaxis. Compared with the other 561
patients, the mean age in their group was significantly
older (68.9 years vs. 55.3 years); the serum level of IgG
was significantly lower (1,496 mg/dl vs. 1,619 mg/dl);
the dose of MTX was significantly lower (6.09 mg vs.
7.28 mg); and the ratios of patients treated with gluco-
corticoids, PCP complicated with coexisting pulmonary
disease and PCP complicated with DM were significantly
higher (53.9% vs. 40.8%, 72.3% vs. 29.1% and 21.3% vs.
10.5%, respectively).
Next, we analyzed the clinical and laboratory records of
the 561 patients who did not receive TMP/SMX prophy-
laxis (Figure 1 and Table 3). The patients in the PCP
group (n = 9) were significantly older, had a higher per-
centage of coexisting pulmonary disease, had a higher
serum level of KL-6 and were treated with a higher PSL
dose than the patients in the non-PCP group (n = 552). In
the PCP group, the percentage of patients treated with
glucocorticoids was significantly higher than that in the
non-PCP group. There were no significant differences in
the duration of morbidity , RA DAS28 score, percentage
of patients with DM, dose of MTX or serum IgG level be-
tween the PCP and non-PCP groups. Because of the low
incidence of PCP, we could not analyze the differences as-
sociated with each biologic therapy as a risk factor for
PCP. The logistic regression analysis revealed that, among
patients with PCP, the hazard ratio (HR) for patients at
least 65 years of age was 4.37 (95% confidence interval
(CI) = 1.04 to 18.2), the HR for those with coexisting pul-
monary disease was 8.13 (95% CI = 1.63 to 40.0) and the











score (ESR) PSL (mg) KL-6 (U/ml)
1 IFX 71 Female 72 10 (−) (−) 6.24 2.5 ND
2 IFX 78 Female 79 1 (+) (−) 6.99 1.0 178
3 IFX 62 Male 21 20 (+) (−) 7.40 2.0 893
4 IFX 78 Female 40 1 (+) (−) 8.04 8.0 398
5 IFX 57 Male 5 2 (+) (−) 3.38 0 304
6 ETN 73 Male 2 3 (+) (−) 7.20 50 366
7 ETN 59 Female 252 15 (−) (−) 5.60 1.0 224
8 ETN 75 Male 132 5 (+) (−) 6.75 5.0 624
9 TCZ 73 Male 84 8 (+) (−) 7.00 10 445
Mean 69.5 76.3 7.2 7/9 0/9 6.51 8.83 429
aPCP developed in nine patients who did receive trimethoprim/sulfamethoxazole prophylaxis. Eight of nine patients were given glucocorticoids. −: Without DM; +:
With DM; DAS28: Disease Activity Score in 28 joints; DM: Diabetes mellitus; ESR: Erythrocyte sedimentation rate; ETN: Etanercept; IFX: Infliximab; PCP: Pneumocystis
pneumonia; PSL: Prednisolone; RA: Rheumatoid arthritis; TCZ: Tocilizumab. bRA duration was measured between the onset of RA and the initiation of biologics.
cTreatment duration was measured between the initiation of biologics and PCP development.
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90.9) (Figure 2).
We calculated the sensitivity and specificity of these risk
factors as tests to represent the incidence of PCP. The
group of patients with one or more risk factors for PCP
includes all patients with PCP, in addition to many pa-
tients without PCP (sensitivity = 100%, specificity = 34.1%).
If prophylaxis were given only to patients with three risk
factors, we would have missed four of nine patients with
PCP (sensitivity = 55.6%, specificity = 94.4%). On the basis
of these results, we assumed that patients with two or
three risk factors could benefit from prophylaxis with
TMP/SMX (sensitivity = 77.8%, specificity = 76.1%). As-
suming that TMP/SMX inhibits the development of PCPFigure 1 Schematic of the study protocol. The 141 patients
treated with prophylaxis trimethoprim/sulfamethoxazole (TMP/SMX
(+)) were excluded from the analysis, and the 561 patients who did
not receive prophylaxis (TMP/SMX (−)) were analyzed to reveal risk
factors for Pneumocystis pneumonia (PCP).completely, the number needed to treat to prevent one
case of PCP was 19.9 in the analysis of 561 patients.
Second study demonstrated effectiveness of prophylaxis
protocol
The inclusion criteria for PCP prophylaxis were applied
for 214 patients with RA for whom treatment with bio-
logic agents was initiated between October 2009 and
September 2010. The mean age of the 214 patients (67
patients treated with IFX, 51 with ETN, 64 with ADA
and 32 with TCZ) was calculated for 174 females (81.3%)
and 40 males (18.7%). The mean age in this group was
58.9 years (range = 15 to 89 years). The mean observa-
tion period was 5.7 months. The mean (±SD) DAS28
(ESR) score was 5.45 ± 1.27, and the mean duration
of RA was 92.9 ± 119 months. A total of 94 patients
(43.9%) received prophylaxis against PCP. Of the 214 pa-
tients, 141 (65.8%) had coexisting pulmonary disease
and 49 (22.9%) received glucocorticoid therapy, and the
mean glucocorticoid dose (converted to the PSL equiva-
lent) was 6.28 mg ± 6.46 mg. In this group of 214 pa-
tients, 87.9% were given MTX and the average dose of
MTX was 9.51 mg/wk.
Among the primary prophylactic group (94 patients),
12 patients (12.8%) received prophylaxis with inhaled
aerosolized pentamidine starting from the initiation
period for the following reasons: four patients had renal
dysfunction, four had cytopenia and four had other con-
ditions. Among the patients who received prophylaxis
with TMP/SMX (82 patients), adverse events occurred
in 11 patients (13.4%). These side effects included liver
dysfunction (five patients), cytopenia (two patients), skin
eruption (one patient), renal dysfunction (one patient),
hyponatremia (one patient) and an unspecified other
Table 3 Comparison of baseline characteristics of patients with vs. without Pneumocystis pneumonia in no-prophylaxis
groupa
Characteristics PCP group Non-PCP group P-value
Patients (n) 9 552
Observation period (person-years) 12.5 839.4
Age (years) 69.5 ± 7.63 57.9 ± 14.1 0.001
Duration of RA (months) 76.3 ± 73.8 112.9 ± 116.5 0.634
DAS28 score (ESR) 6.51 ± 1.28 5.85 ± 1.29 0.060
Coexisting pulmonary disease (%) 77.8 28.1 0.002
Diabetes mellitus (%) 0.00 10.7 0.156
Dose of prednisolone (mg) 8.83 ± 14.9 1.70 ± 2.57 0.004
Glucocorticoids (%)b 88.9 39.9 0.009
Dose of methotrexate (mg/w) 6.56 ± 5.23 7.29 ± 4.10 0.695
Serum level of IgG (mg/dl) 1,600 ± 714 1,620 ± 511 0.660
Serum level of KL-6 (U/ml) 429 ± 218 257 ± 138 0.008
aDAS28: Disease Activity Score in 28 joints; ESR: Erythrocyte sedimentation rate; IgG: immunoglobulin G; PCP: Pneumocystis pneumonia; RA: Rheumatoid arthritis.
bGlucocorticoid data are percentages of patients treated with glucocorticoids.
Patient age, the complication of pulmonary disease, the use and dose of glucocorticoids and the serum level of KL-6 were significantly different between the two
groups. Data are mean ± SD by Wilcoxon rank-sum test unless otherwise specified.
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changed to inhaled aerosolized pentamidine in all 11 of
these patients. There were no severe adverse events that
required hospital admission. The observation period was
continued after TMP/SMX withdrawal.
It is noteworthy that, during the observation period,
no case of PCP was observed among the patients in the
second study. Compared with the results of the first
analysis of 702 patients, the incidence of PCP decreased
from 1.28% (9 of 702 patients) and 0.93/100 patient-
years to 0.00% and 0/100 patient years, which confirms






The duration of RA
Figure 2 Graph showing three risk factors for Pneumocystis pneumon
65 years (hazard ratio (HR) = 4.37, 95% confidence interval (CI) = 1.04 to 18.2
the use of glucocorticoids (HR = 11.4, 95% CI = 1.38 to 90.9). The Disease Ac
(ESR)) and the duration of rheumatoid arthritis (RA) were not risk factors foDiscussion
It is well-known that HIV patients with a CD4+ cell
counts less than 200 cells/mm3 are likely to develop PCP,
and the most common identifiable risk factor for develop-
ing PCP in patients with autoimmune disease or malig-
nancy is glucocorticoid use [9,10]. Ogawa et al. reported
that the number of peripheral lymphocytes at 2 weeks
after initiation of glucocorticoid treatment, not the num-
ber at the initiation of treatment, was a risk factor for PCP
in patients with rheumatic diseases [11]. Other reports
and some postmarketing surveillance studies have re-







ia. Logistic regression analysis identified three risk factors: age at least
), coexisting pulmonary disease (HR = 8.13, 95% CI = 1.63 to 40.0) and
tivity Score in 28 joints (DAS28) score (erythrocyte sedimentation rate
r Pneumocystis pneumonia.
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of lymphocytes as a risk factor from the analysis.
The postmarketing surveillance of IFX revealed that the
development of PCP in RA patients treated with IFX was
best predicted by an age of at least 65 years, dose of glu-
cocorticoids (≥6 mg of PSL) and coexisting pulmonary
disease [12]. However, that report was restricted to
patients treated with IFX and did not include patients re-
ceiving other TNFα inhibitors or an IL-6 inhibitor. After
analyzing the patients treated with biologic therapy who
developed PCP in this study, we found that four of nine
patients had fewer than two of the above-mentioned risk
factors.
In our present study, we identified various risk factors
for PCP in patients treated with biologics, including not
only TNFα inhibitors but also the IL-6 inhibitor, to
establish a new and useful prophylactic TMP/SMX pro-
cedure for PCP. We retrospectively compared a PCP
group with a non-PCP group in patients who did not re-
ceive prophylaxis, and the multivariate analysis revealed
that an age of at least 65 years, coexisting pulmonary
disease and use of glucocorticoids were risk factors for
PCP. An age of at least 65 years and coexisting pulmon-
ary disease were also risk factors in the IFX postmar-
keting surveillance report; however, in our present study,
the use of glucocorticoids alone was abstracted as a risk
factor without regard to the dose administered. Other
researchers have shown that, among patients with inter-
stitial pneumonia or autoimmune disease, the gluco-
corticoid dose (≥30 mg of PSL) was a risk factor for PCP
development [3,11]. In our study, eight of the nine pa-
tients who developed PCP were receiving glucocorti-
coids, but only two patients were given at least 6 mg of
PSL. The other six patients were treated with less than
6 mg of PSL (1.0 mg to 5.0 mg), suggesting that patients
treated with glucocorticoids can benefit from primary
TMP/SMX prophylaxis of PCP, regardless of glucocor-
ticoid dose.
A previous report revealed that patients treated with
high-dose glucocorticoids, those receiving immunosup-
pressive agents and those with lower serum IgG levels had
a significantly higher risk for developing PCP [13]. An-
other recent report identified an advanced radiographic
stage as a risk factor for PCP in RA patients treated with
ADA [14]. In the present study, however, there were no
significant differences in the serum IgG level or the radio-
graphic stage between the patients with versus without
PCP. Although concomitant MTX treatment was identi-
fied as an independent risk factor for PCP in a report of
RA patients in Japan who were treated with ETN [15], the
use (yes or no) or dose of MTX was not found to be a risk
factor for the development of PCP in our patient cohort.
The duration between the initiation of biologics and PCP
development varied widely, from 2 weeks to 20 months. Inprevious reports of RA patients treated with biologics, 76%
to 90% of the cases of PCP developed within 6 months
after the initiation of biologics [14-16]. In our present
study, PCP developed in two of nine patients more than
12 months after biologics were started. That finding sug-
gests that TMP/SMX prophylaxis needs to be continued
for long periods.
A total of 250 (35.6%) of the 702 patients had two or
three risk factors for PCP in this study. If patients with
at least one risk factor were started on TMP/SMX
prophylaxis in our study, 513 (73.1%) of the patients
would have been included in the prophylaxis group. We
thought that including these patients would have been
difficult because of the adverse effects of the prophylac-
tic treatment.
In the analysis of 214 patients, the duration of RA was
shorter and the DAS28 score (ESR) was lower than those
of the 702 patients. These findings could be due to our
becoming more proactive about using biologic agents in
patients with RA during the early stage of the disease.
After adoption of the inclusion criteria for PCP prophy-
laxis, the ratio of glucocorticoid use decreased and the
MTX dose increased, suggesting that an adequate dosage
of MTX led to a tendency toward decreased glucocor-
ticoid use in patients with RA. Almost all of the patients
underwent CT, and we were more proactive about using
biologic agents in patients with complications after the
adoption of the prophylactic criteria. This is why the
percentage of pulmonary disease was much higher in the
214 patients than that in the analysis of 702 patients.
Under the new prophylactic criteria, 94 (43.9%) of 214
patients were given prophylaxis and no severe adverse
events occurred. After the adoption of the criteria for PCP
prophylaxis, none of the patients developed PCP and the
incidence of PCP was reduced from 0.93/100 patient-years
to 0.00, confirming the validity and the safety of the pri-
mary prophylactic procedure in daily clinical practice.
Authors of a previous report found that 3.1% of patients
were forced to stop TMP/SMX prophylaxis because of ad-
verse events [17]. The development of adverse events fol-
lowing TMP/SMX treatment were unavoidable in our
present study, but we found that inhaled aerosolized pent-
amidine could be used as an alternative prophylactic treat-
ment, rather than biologics, for PCP in patients with RA.
There are some limitations associated with this study.
First, we treated only nine patients with PCP A larger
number of patients and a longer observation period are
necessary to confirm the effectiveness of our protocol. By
the statistical calculation, we found that we needed 369
patients to confirm the statistical significance of the differ-
ence in the incidence of PCP in the first cohort (1.28%).
Second, Pneumocystis colonization, which was previously
reported to be a possible risk factor for PCP, was not ana-
lyzed in this study. The number of lymphocytes also was
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risk factors for PCP development, we excluded 141 pa-
tients who received TMP/SMX, although this exclusion
might have led to biased results regarding the identifica-
tion of risk factors. The serum level of IgG and the ratio
of patients with DM complications were significantly dif-
ferent between the excluded 141 patients and 561 patients,
respectively. These results suggest that if all 141 patients
had not received the prophylaxis and the incidence of
PCP had been much higher than 1.28%, the lower IgG
level or the complication with DM might have been risk
factors for PCP.
The incidence of PCP is much lower in Western coun-
tries than in Japan. Given the adverse effects of TMP/
SMX, the prophylaxis criteria used in this study cannot
be applied to patients in other countries in which the in-
cidence of PCP is quite different from that in Japan.
Additional studies are required to determine the inci-
dence and risk factors for PCP in Western countries.
Conclusions
The results of the first analysis in this study show that
there are three major risk factors for the development of
PCP in patients with RA receiving biologics. They reveal
that patients with two or three risk factors could benefit
from TMP/SMX prophylaxis against PCP. We also show
the prophylactic effectiveness and safety of the inclusion
criteria. In patients 65 years of age or older, coexisting
pulmonary disease and the use of glucocorticoids were
identified as risk factors for PCP in RA patients being
treated with biologics. Patients with two or three risk
factors are therefore considered to benefit from primary
prophylaxis against PCP. However, the number of pa-
tients was too low, so this prophylactic procedure needs
to continue to be applied to further investigate its vali-
dity and safety.
Abbreviations
ADA: Adalimumab; BALF: Bronchoalveolar lavage fluid; CT: Computed
tomography; DAS: Disease Activity Score; ETN: Etanercept; IFX: Infliximab;
IL: Interleukin; MTX: Methotrexate; PCP: Pneumocystis pneumonia;
PSL: Prednisolone; RA: Rheumatoid arthritis; TCZ: Tocilizumab; TMP/
SMX: Trimethoprim/sulfamethoxazole; TNFα: Tumor necrosis factor α.
Competing interests
YT has received consulting fees, speaking fees and/or honoraria from Chugai
Pharma, Mitsubishi-Tanabe Pharma, Eisai Pharma, Pfizer, Abbott Immunology
Pharma, Janssen Pharma, Takeda Industrial Pharma, Astra-Zeneca, Astellas
Pharma, Asahi-kasei Pharma and GlaxoSmithKline, and he has received
research grant support from Bristol-Myers Squibb, Mitsubishi-Tanabe Pharma,
MSD, Takeda Industrial Pharma, Astellas Pharma, Eisai Pharma, Chugai
Pharma, Pfizer and Daiichi-Sankyo.
Authors’ contributions
TK acquired, analyzed and interpreted data; performed the statistical analysis;
and wrote and revised the manuscript. SK and MN acquired, analyzed and
interpreted data; performed the statistical analysis; and drafted the
manuscript. KS interpreted data and edited and revised the manuscript.
YT designed the study, interpreted data and edited the manuscript.
All authors read and approved the final manuscript.Acknowledgements
The authors thank all of the medical staff members at the associated
institutions for providing the data.
Received: 28 July 2013 Accepted: 28 January 2014
Published: 5 February 2014References
1. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y,
Yamanaka H, Fujii K, Yoshinaga T, Freundlich B, Suzukawa M: Postmarketing
surveillance of safety and effectiveness of etanercept in Japanese
patients with rheumatoid arthritis. Mod Rheumatol 2011, 21:343–351.
2. Ward MM, Donald F: Pneumocystis carinii pneumonia in patients with
connective tissue disease: the role of hospital experience in diagnosis
and mortality. Arthritis Rheum 1999, 42:780–789.
3. Takabayashi K, Koike T, Kurasawa K, Yamazaki S, Sugiyama T, Matsumura R,
Yoshida H, Tomioka H, Yoshida S, Oshima H: [Pulmonary opportunistic
infections in patients with autoimmune diseases] [in Japanese].
Nihon Naika Gakkai Zasshi 1989, 78:1293–1298.
4. Thomas CF Jr, Limper AH: Pneumocystis pneumonia: clinical presentation
and diagnosis in patients with and without acquired immune deficiency
syndrome. Semin Respir Infect 1998, 13:289–295.
5. Velayos FS, Sandborn WJ: Pneumocystis carinii pneumonia during
maintenance anti-tumor necrosis factor-α therapy with infliximab for
Crohn’s disease. Inflamm Bowel Dis 2004, 10:657–660.
6. Seddik M, Meliez H, Seguy D, Viget N, Cortot A, Colombel JF: Pneumocystis
jirovecii (carinii) pneumonia following initiation of infliximab and
azathioprine therapy in a patient with Crohn’s disease. Inflamm Bowel Dis
2004, 10:436–437.
7. Kaur N, Mahl TC: Pneumocystis carinii pneumonia with oral candidiasis
after infliximab therapy for Crohn’s disease. Dig Dis Sci 2004, 49:1458–
1460.
8. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H,
Kamatani N, Harigai M, Ryu J, Inoue K, Kondo H, Inokuma S, Ochi T, Koike T:
Postmarketing surveillance of the safety profile of infliximab in 5000
Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008,
67:189–194.
9. Yale SH, Limper AH: Pneumocystis carinii pneumonia in patients without
acquired immunodeficiency syndrome: associated illness and prior
corticosteroid therapy. Mayo Clin Proc 1996, 71:5–13.
10. Worth LJ, Dooley MJ, Seymour JF, Mileshkin L, Slavin MA, Thursky KA:
An analysis of the utilisation of chemoprophylaxis against Pneumocystis
jirovecii pneumonia in patients with malignancy receiving corticosteroid
therapy at a cancer hospital. Br J Cancer 2005, 92:867–872.
11. Ogawa J, Harigai M, Nagasaka K, Nakamura T, Miyasaka N: Prediction of and
prophylaxis against Pneumocystis pneumonia in patients with connective
tissue diseases undergoing medium- or high-dose corticosteroid
therapy. Mod Rheumatol 2005, 15:91–96.
12. Harigai M, Koike R, Miyasaka N, Pneumocystis Pneumonia under Anti-Tumor
Necrosis Factor Therapy (PAT) Study Group: Pneumocystis pneumonia
associated with infliximab in Japan. N Engl J Med 2007, 357:1874–1876.
13. Sato T, Inokuma S, Maezawa R, Nakayama H, Hamasaki K, Miwa Y, Okazaki Y,
Yamashita M, Tanaka Y, Kono H: Clinical characteristics of Pneumocystis
carinii pneumonia in patients with connective tissue diseases.
Mod Rheumatol 2005, 15:191–197.
14. Watanabe K, Sakai R, Koike R, Sakai F, Sugiyama H, Tanaka M, Komano Y,
Akiyama Y, Mimura T, Kaneko M, Tokuda H, Iso T, Motegi M, Ikeda K, Nakajima H,
Taki H, Kubota T, Kodama H, Sugii S, Kuroiwa T, Nawata Y, Shiozawa K, Ogata A,
Sawada S, Matsukawa Y, Okazaki T, Mukai M, Iwahashi M, Saito K, Tanaka Y, et al:
Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia
in patients with rheumatoid arthritis receiving adalimumab: a retrospective
review and case–control study of 17 patients. Mod Rheumatol 2013,
23:1085–1093.
15. Tanaka M, Sakai R, Koike R, Komano Y, Nanki T, Sakai F, Sugiyama H,
Matsushima H, Kojima T, Ohta S, Ishibe Y, Sawabe T, Ota Y, Ohishi K,
Miyazato H, Nonomura Y, Saito K, Tanaka Y, Nagasawa H, Takeuchi T,
Nakajima A, Ohtsubo H, Onishi M, Goto Y, Dobashi H, Miyasaka N,
Harigai M: Pneumocystis jirovecii pneumonia associated with etanercept
treatment in patients with rheumatoid arthritis: a retrospective review of
15 cases and analysis of risk factors. Mod Rheumatol 2012, 22:849–858.
Katsuyama et al. Arthritis Research & Therapy 2014, 16:R43 Page 8 of 8
http://arthritis-research.com/content/16/1/R4316. Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, Sekiguchi N,
Inoo M, Onishi I, Ohashi H, Amamoto F, Miyata M, Ohtsubo H, Hiramatsu K,
Iwamoto M, Minota S, Matsuoka N, Kageyama G, Imaizumi K, Tokuda H,
Okochi Y, Kudo K, Tanaka Y, Takeuchi T, Miyasaka N: Pneumocystis jirovecii
pneumonia in patients with rheumatoid arthritis treated with infliximab:
a retrospective review and case–control study of 21 patients.
Arthritis Rheum 2009, 61:305–312.
17. Green H, Paul M, Vidal L, Leibovici L: Prophylaxis of Pneumocystis
pneumonia in immunocompromised non-HIV-infected patients:
systematic review and meta-analysis of randomized controlled trials.
Mayo Clin Proc 2007, 82:1052–1059.
doi:10.1186/ar4472
Cite this article as: Katsuyama et al.: Prophylaxis for Pneumocystis
pneumonia in patients with rheumatoid arthritis treated with biologics,
based on risk factors found in a retrospective study. Arthritis Research &
Therapy 2014 16:R43.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
